Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Genexine, Inc.

Market Cap 243B 160M 138M 128M 119M 224M 15.23B 227M 1.51B 587M 7.41B 601M 589M 25.67B P/E Ratio 2022
-8.34x
P/E Ratio 2023 -5.99x
Enterprise Value 246B 162M 140M 129M 121M 226M 15.41B 230M 1.52B 594M 7.5B 609M 596M 25.98B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
81.34%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-15 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
25-09-30 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-09-22 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-03-07 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
24-09-30 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
24-07-04 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
24-06-25 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
24-05-14 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
23-11-14 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-10-23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
23-08-31 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day-0.50%
1 week-10.03%
Current month-17.90%
1 month-40.38%
3 months-38.49%
6 months-40.26%
Current year-35.86%
1 week 2,815
Extreme 2815
3,290
1 month 2,815
Extreme 2815
5,070
Current year 2,815
Extreme 2815
7,490
1 year 2,815
Extreme 2815
7,490
3 years 2,815
Extreme 2815
12,300
5 years 2,815
Extreme 2815
75,538.46
10 years 2,815
Extreme 2815
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 2025-03-25
Chief Executive Officer 61 2023-01-26
Corporate Officer/Principal 49 2021-12-31
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 2022-03-28
Director/Board Member 61 2023-01-26
Date Insider Type Main position Quantity % Market Cap.
24-10-21Others 156,632 0.3773%
24-10-21Others

Chief Executive Officer

1,691,165 4.0741%
24-10-21Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%-10.03%-38.67%-74.45% 90.16M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.57%+2.46%+21.08%+86.55% 21.38B
Weighted average by Cap. +1.72%+2.37%+32.01%+99.52%

Financials

2022 2023
Net sales 16.14B 10.65M 9.2M 8.47M 7.93M 14.87M 1.01B 15.1M 100M 39.01M 493M 39.96M 39.11M 1.71B 4.43B 2.92M 2.52M 2.32M 2.18M 4.08M 278M 4.14M 27.45M 10.7M 135M 10.96M 10.73M 468M
Net income -55.97B -36.93M -31.89M -29.39M -27.51M -51.56M -3.51B -52.36M -347M -135M -1.71B -139M -136M -5.92B -66.87B -44.12M -38.11M -35.11M -32.87M -61.6M -4.19B -62.55M -415M -162M -2.04B -166M -162M -7.07B
Net Debt 62.14B 41M 35.41M 32.63M 30.54M 57.24M 3.9B 58.12M 385M 150M 1.9B 154M 151M 6.57B 2.94B 1.94M 1.68M 1.55M 1.45M 2.71M 185M 2.75M 18.26M 7.12M 89.89M 7.29M 7.14M 311M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
26-06-12 3,005.00 -0.50% 170,015
26-06-11 3,020.00 +1.00% 102,381
26-06-10 2,990.00 -0.66% 121,012
26-06-09 3,010.00 +5.99% 285,657
26-06-08 2,840.00 -14.97% 649,282
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!